Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05786573
Other study ID # ZB012-03-002
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 25, 2023
Est. completion date June 8, 2026

Study information

Verified date May 2024
Source Zenas BioPharma (USA), LLC
Contact Patient and Medical Information
Phone 833-269-4696
Email clinicaltrialsinfo@zenasbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).


Description:

This study consists of a 6-month open label Safety and Dose Confirmation Run-in Period (SRP), 6-month Randomized Control Period (RCP), and an additional 1-year open-label extension (OLE) period. To enter the Screening Period (Day -28 to Day -1) in the SRP or RCP, patients must have a clinical diagnosis of primary or secondary wAIHA due to an underlying autoimmune disorder, have failed at least 1 prior wAIHA treatment regimen, and have a Hgb level of ≥ 7 to < 10 g/dL with at least one sign or symptom of anemia. For the SRP only, patients with secondary wAIHA due to underlying lymphoproliferative disease may be eligible if they are receiving stable treatment. All patients in the SRP or RCP are allowed to continue up to 2 failed wAIHA therapies throughout the 24-week study. On Day 1 of the SRP, patients receive obexelimab administered as subcutaneous (SC) injections. On Day 1 of the RCP, patients will be randomized in a ratio of 1:1 to receive either obexelimab or placebo administered as subcutaneous (SC) injections. Patients must return to the study site for the first 5 weeks and then every 2 weeks thereafter. Patients will undergo assessments for efficacy, safety, PK, PD, and immunogenicity during the 24-week SRP or RCP. Following the 24-week SRP or RCP, patients will have the opportunity to receive obexelimab for up to 52 weeks in the Open Label Extension (OLE) Period. Including screening and follow-up, the maximum duration of participation in this study for an individual patient is 81 weeks (i.e., 28-day screening, 24-week SRP or RCP, 52-week OLE, and an 8-week follow-up).


Recruitment information / eligibility

Status Recruiting
Enrollment 134
Est. completion date June 8, 2026
Est. primary completion date March 14, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males and females, = 18 years of age 2. Clinically diagnosed with wAIHA for at least 3 months and currently receiving treatment for wAIHA or have previously received treatment for wAIHA. 3. Diagnosis of primary or secondary wAIHA documented by a positive direct antiglobulin test specific for anti-IgG or anti-IgA. 4. Failed at least 1 prior wAIHA treatment regimen. 5. At least one sign or symptom of anemia as assessed by the investigator at screening. 6. Other inclusion criteria apply. Exclusion Criteria: 1. Have cold antibody AIHA, cold agglutinin syndrome, mixed type (i.e., warm, and cold) AIHA, or paroxysmal cold hemoglobinuria. 2. Have any other associated cause of hereditary or acquired hemolytic anemia. 3. For the RCP only, patients with secondary wAIHA not due to autoimmune disorders, including LPDs. 4. Received a transfusion within 2 weeks prior to randomization. 5. Use of B cell-depleting, B cell-targeted, or other biologic immunomodulatory agents within the 6 months prior to randomization. 6. Received IV Ig or epoetin alfa within 6 weeks prior to randomization. 7. Receiving more than 2 concomitant medications for the treatment of wAIHA. 8. Other exclusion criteria apply.

Study Design


Intervention

Drug:
Obexelimab
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and Fc?RIIb, resulting in down regulation of B cell activity.
Obexelimab
Obexelimab is a monoclonal antibody that simultaneously binds CD19 and Fc?RIIb, resulting in down regulation of B cell activity.
Other:
Placebo
Placebo

Locations

Country Name City State
Italy Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano
Italy A.O.U. Maggiore della Carità Novara Piemonte
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino Torino
Italy Azienda Sanitaria Universitaria Giuliano Isontina Udine Friuli-Venezia Giulia
Japan Fukushima Medical University Hospital Fukushima
Japan Japanese Red Cross Society Himeji Hospital Himeji Hyogo
Japan Kanazawa University Hospital Kanazawa Ishikawa
Japan Hospital of the University of Occupational & Environmental Health Kitakyushu Hukuoka
Japan Okayama University Hospital Okayama
Japan Kitasato University Hospital Sagamihara Kanagawa
Japan Tohoku University Hospital Sendai Miyagi
Japan Osaka University Hospital Suita Osaka
Poland Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii Gdansk Pomorskie
Poland Uniwersyteckie Centrum Kliniczne - Ul. Smoluchowskiego 17 Gdansk
Poland SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Olsztyn Warminsko-mazurskie
Spain Hospital Universitario Germans Trias i Pujol Badalona Barcelona
Spain Hospital Universitario de Burgos Burgos
Spain Hospital Universitario de Gran Canaria Doctor Negrin Las Palmas De Gran Canaria Las Palmas
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario de Navarra Pamplona Navarra
Spain Hospital Universitario Virgen del Rocio Sevilla
Spain Hospital Universitario Virgen del Rocio - PPDS Sevilla
Taiwan Changhua Christian Hospital Chang Hua Changhua
Taiwan Chi Mei Medical Center, Liouying Tainan
Taiwan National Cheng Kung University Hospital Tainan
Taiwan National Taiwan University Hospital Taipei
Turkey Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi Ankara
Turkey Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi Samsun
Turkey Karadeniz Technical University Faculty of Medicine Trabzon
United Kingdom Kent and Canterbury Hospital Canterbury Kent
United Kingdom Leicester Royal Infirmary Leicester Leicestershire
United Kingdom Barts Health NHS Trust London
United Kingdom University College London Hospitals London
United Kingdom Plymouth Hospitals NHS Trust Plymouth Devon
United States Mercy Health Lacks Cancer Center Grand Rapids Michigan
United States East Carolina University Greenville North Carolina
United States MD Anderson Cancer Center Houston Texas
United States University of Iowa Iowa City Iowa
United States Regents of the University of California Los Angeles Los Angeles California
United States University of Southern California Los Angeles California
United States Memorial Sloan Kettering New York New York
United States Integris Southwest Medical Center Oklahoma City Oklahoma
United States Mayo Clinic Rochester Minnesota
United States University of California San Diego Moores Cancer Center San Diego California
United States Georgetown University Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Zenas BioPharma (USA), LLC

Countries where clinical trial is conducted

United States,  Italy,  Japan,  Poland,  Spain,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Dose Confirmation Run-in Period (SRP) Proportion of participants with hemoglobin (Hgb) = 10 g/dL and = 2 g/dL increase from Baseline with no use of blood transfusion or glucocorticoid (GC) rescue therapy. 24 weeks
Primary Randomized Control Period (RCP) Proportion of participants who achieve a durable Hgb response (defined as Hgb = 10 g/dL and = 2 g/dL increase from Baseline on at least 3 of 4 consecutive available visits), at the earliest on or after Week 12, with no use of blood transfusion or GC rescue therapy prior to attaining durable response through Week 24. 24 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT03965624 - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Phase 2
Recruiting NCT05922839 - Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA Phase 2
Completed NCT01181154 - Rituximab in Auto-Immune Hemolytic Anemia Phase 3
Recruiting NCT05925023 - Sirolimus in the Treatment of Refractory/Relapsed wAIHA Phase 2
Recruiting NCT05757570 - An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias Phase 1/Phase 2
Withdrawn NCT04256148 - ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia Phase 2
Terminated NCT03075878 - A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) Phase 1/Phase 2
Withdrawn NCT04956276 - Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia Phase 2
Completed NCT03226678 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Phase 2
Recruiting NCT04119050 - Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia Phase 2/Phase 3
Terminated NCT04253236 - To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). Phase 2
Temporarily not available NCT05221619 - Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)